This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second View: Examining the recent data from the PIONEER Trial of Blueprint's AYVAKIT (avapritinib) in treating patients with Indolent Systemic Mastocytosis

Ticker(s): BPMC

Who's the expert?

Institution: Mayo Clinic

  • Research Chair, Division of Allergic Disease, Associate Program Director of Allergy/Immunology & Assistant Professor at the Mayo Clinic.
  • Treats 75 patients with indolent systemic mastocytosis.
  • Translational research involves pathophysiologic mechanisms and treatment of hypereosinophilic syndromes and eosinophil-associated disorders and mast cell mediators for the evaluation, monitoring and treatment of systemic mastocytosis.

Interview Goal
This conversation will focus on Blueprint Medicines' Ayvakit (avapritinib) in treating indolent systemic mastocytosis. We'll take a deeper look at the results from the PIONEER trial presented at the 2023 AAAAI Annual Meeting.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.